Expired activity
Please go to the PowerPak
homepage and select a course.
Improving Efficacy in First-Line Treatment of Advanced Melanoma: Focus on the Role of Immune Checkpoint Inhibitors
Optimal Treatment of Advanced Melanoma in the First-line Setting (Part 1 of a 2-Part Interactive Monograph Series)
This educational activity is sponsored by Postgraduate Healthcare Education, LLC (PHE) and supported by an educational grant from Bristol Myers Squibb.
FACULTY
Jordan P. McPherson, PharmD, MS, BCOP
Oncology Clinical Pharmacist, Melanoma & Non-melanoma Skin Cancer
Huntsman Cancer Institute
Adjunct Assistant Professor
University of Utah College of Pharmacy
Salt Lake City, Utah
FINANCIAL DISCLOSURE
Dr. McPherson has no relevant affiliations or financial relationships with a commercial interest to disclose.
The clinical reviewer, Megan May, PharmD, BCOP has disclosed that she has no actual or potential conflicts of interest related to this program.
Susanne Batesko, RN, BSN, Robin Soboti, RPh, and Susan R. Grady, MSN, RN, as well as the planners, managers, and other individuals, not previously disclosed, who are in a position to control the content of Postgraduate Healthcare Education (PHE) continuing education (CE) activities hereby state that they have no relevant conflicts of interest and no financial relationships or relationships to products or devices during the past 12 months to disclose in relation to this activity. PHE is committed to providing participants with a quality learning experience and to improve clinical outcomes without promoting the financial interests of a proprietary business.
ACCREDITATION STATEMENTS
PHARMACY
Postgraduate Healthcare Education, LLC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
UAN: 0430-0000-22-038-H01-P
Credits: 1.0 hour (0.1 ceu)
Type of Activity: Application
Media: Internet
Fee Information: There is no fee for this educational activity
Estimated time to complete activity: 60 minutes
Published
May 20, 2022
Expires
November 20, 2022
TARGET AUDIENCE
This accredited activity has been designed for oncology pharmacist.
HOW TO OBTAIN CREDIT
During the period May 20, 2022 to November 20, 2022, participants must 1) read the learning objectives and faculty disclosures; 2) view the educational activity; and 3) complete the posttest and evaluation form directly after the activity within a maximum of 60 days of participating in the activity. To answer the questions, click on your selected choice for each answer then proceed to the next question. Once completed, click on the Grade Exam button at the bottom of the page. Your posttest will automatically be graded. If you successfully complete the posttest (score of 70% or higher), your statement of participation will be made available immediately. Click on the View Statement of Participation link and print the statement for your records. If you receive a score lower than 70%, you will receive a message notifying you that you did not pass the posttest. You will have 2 opportunities to pass the posttest. To receive Credit, you must provide your date of birth and NABP number. All Credit information will be uploaded into CPE monitor within 30 days.
SPECIAL NOTE
Learners claiming ACPE-credit for this activity will be invited (by email in July or October 2022) to participate in a small group virtual Q&A session (PowerUp LIVE) with the faculty in August or December 2022. Each PowerUp LIVE session is ACPE-accredited for 0.5 credit hours. Participation in these sessions will be limited.
Goal
The goal of this educational series is to provide oncology pharmacists with advanced and up-to-date knowledge of new clinical evidence for the use of immune checkpoint inhibitors (ICIs) in advanced melanoma, including mechanisms of drug action, approved indications, use in first-line therapy, and adverse drug effects, which will serve to optimize patient outcomes and quality of life.
EDUCATIONAL OBJECTIVES
Upon completion of this program, participants should be better able to:
- Explain the mechanisms of action and current role of ICIs in first-line treatment of advanced melanoma
- Summarize the primary literature supporting use of ICIs in first-line monotherapy and combination therapy regimens for advanced melanoma
- Propose a patient-specific therapeutic strategy to individualize treatment for advanced melanoma based on drug-related factors and clinical characteristics
REQUIRED COMPUTER HARDWARE/SOFTWARE
Please ensure the computer system you plan to use meets the following minimum requirements:
- Operating System: Windows 98 or higher & Macintosh 2.2 or higher
- Internet Browser (Mac & Windows): Internet Explorer 6.0 or higher, Google Chrome, Safari 5.0.6 or higher, Firefox 3.0.3 or higher, & Opera 5 or higher
- Broadband Internet connection: Cable, High-speed DSL & any other medium that is internet accessible
- Peripherals: Computer speakers or headphones
- Monitor Screen Resolution: 320 x 480 or higher
- Media Viewing Requirements: Adobe Reader, Microsoft PowerPoint, Flash Player & HTML5
Disclosure of Unlabeled Use and Disclaimer
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of Postgraduate Healthcare Education, LLC or Bristol Myers Squibb. Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients' conditions, and possible contraindications on dangers in use, (review of any applicable manufacturer's product information) and comparison with recommendations of other authorities.
The author, sponsor, and publisher of this continuing education activity have made all reasonable efforts to ensure that all information contained herein is accurate in accordance with the latest available scientific knowledge at the time of acceptance for publication. However, because information regarding drugs (their administration, dosages, contraindications, adverse reactions, interactions, special warnings, precautions, etc.) is subject to constant change, the reader is advised to check the manufacturer's package insert for information concerning recommended dosages and potential problems and cautions prior to dispensing or administering the drug. Special precautions should be taken when a drug is new, or highly toxic, or is unfamiliar to the dispenser or administrant. This educational activity may contain discussion of published and/or investigational uses of agents that are not approved by the U.S. Food and Drug Administration (FDA). Neither the publisher nor sponsor promotes the use of any agent outside of approved labeling. Statements made in this activity have not been evaluated by the FDA.
